SEC Stock Data Quick Answer AGIOS PHARMACEUTICALS, INC. reported Cash and Equivalents of $89.13 million for fiscal year 2025. AGIOS PHARMACEUTICALS, INC. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $89.13M +16.9% 2024 $76.25M -13.6% 2023 $88.20M -36.7% 2022 $139.26M -31.4% 2021 $203.13M +59.4% 2020 $127.44M +57.5% 2019 $80.93M +14.8% 2018 $70.50M … Read more
Quick Answer AGIOS PHARMACEUTICALS, INC. reported Total Assets of $1.30 billion for fiscal year 2025. AGIOS PHARMACEUTICALS, INC. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $1.30B -22.0% 2024 $1.66B +77.5% 2023 $937.12M -24.3% 2022 $1.24B -13.8% 2021 $1.44B +68.6% 2020 $852.95M -4.2% 2019 $890.74M +3.8% 2018 $858.46M +39.7% 2017 $614.40M … Read more
Quick Answer AGIOS PHARMACEUTICALS, INC. reported Diluted EPS of $7.12 per share (loss) for fiscal year 2025. AGIOS PHARMACEUTICALS, INC. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$7.12 -161.2% 2024 $11.64 +283.9% 2023 -$6.33 -49.6% 2022 -$4.23 -115.9% 2021 $26.55 +660.1% 2020 -$4.74 +30.9% 2019 -$6.86 — Quarterly Diluted EPS … Read more
Quick Answer AGIOS PHARMACEUTICALS, INC. reported Net Income of -$412.78 million for fiscal year 2025. AGIOS PHARMACEUTICALS, INC. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$412.78M -161.3% 2024 $673.73M +291.4% 2023 -$352.09M -51.9% 2022 -$231.80M -114.4% 2021 $1.60B +590.2% 2020 -$327.37M +20.4% 2019 -$411.47M -18.9% 2018 -$346.03M -10.0% 2017 -$314.67M … Read more
Quick Answer AGIOS PHARMACEUTICALS, INC. reported Revenue (ASC 606) of $54.03 million for fiscal year 2025. AGIOS PHARMACEUTICALS, INC. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $54.03M +48.0% 2024 $36.50M +36.1% 2023 $26.82M +88.4% 2022 $14.24M — 2021 $0.00 — 2020 $0.00 -100.0% 2019 $117.91M +24.9% 2018 $94.39M … Read more
Quick Answer AGIOS PHARMACEUTICALS, INC. reported Total Revenue of $54.03 million for fiscal year 2025. AGIOS PHARMACEUTICALS, INC. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $54.03M +48.0% 2024 $36.50M +36.1% 2023 $26.82M +88.4% 2022 $14.24M — 2021 $0.00 — 2020 $0.00 -100.0% 2019 $117.91M +24.9% 2018 $94.39M +119.4% 2017 $43.01M … Read more
Quick Answer AGIOS PHARMACEUTICALS, INC. reported Total Revenue of $54.03 million for fiscal year 2025. AGIOS PHARMACEUTICALS, INC. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $54.03M+48.0% $36.50M+36.1% $26.82M+88.4% $14.24M $0.00 $0.00-100.0% Revenue (ASC 606) $54.03M+48.0% $36.50M+36.1% $26.82M+88.4% $14.24M $0.00 $0.00-100.0% Net Income -$412.78M-161.3% $673.73M+291.4% -$352.09M-51.9% -$231.80M-114.4% $1.60B+590.2% -$327.37M+20.4% … Read more
Quick Answer ABUNDIA GLOBAL IMPACT GROUP, INC. reported Shares Outstanding of 36.92 million shares for fiscal year 2025. ABUNDIA GLOBAL IMPACT GROUP, INC. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 36.92M +16.2% 2024 31.78M +191.4% 2023 10.91M +5.6% 2022 10.33M +4.0% 2021 9.93M +42.3% 2020 6.98M +32.3% 2019 5.28M -89.9% … Read more
Quick Answer ABUNDIA GLOBAL IMPACT GROUP, INC. reported Operating Income of -$28.75 million for fiscal year 2025. ABUNDIA GLOBAL IMPACT GROUP, INC. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2025 -$28.75M -257.2% 2024 -$8.05M -75.7% 2023 -$4.58M -488.9% 2022 -$777.9K +24.8% 2021 -$1.03M +75.3% 2020 -$4.18M -79.2% 2019 -$2.33M -590.5% 2018 … Read more
Quick Answer ABUNDIA GLOBAL IMPACT GROUP, INC. reported R&D Expense of $752.3 thousand for fiscal year 2025. ABUNDIA GLOBAL IMPACT GROUP, INC. R&D Expense — Annual History Fiscal Year R&D Expense YoY Change 2025 $752.3K -54.4% 2024 $1.65M — Quarterly R&D Expense Quarter Ending R&D Expense YoY QoQ September 30, 2024 $111.3K — — ABUNDIA … Read more